Breast cancer screening of pregnant and breastfeeding women with BRCA mutations
- PMID: 28138892
- DOI: 10.1007/s10549-017-4122-y
Breast cancer screening of pregnant and breastfeeding women with BRCA mutations
Abstract
Screening recommendations for women with BRCA mutations include annual breast MRI starting at age 25, with annual mammogram added at age 30. The median age of childbearing in the US is age 28, therefore many BRCA mutation carriers will be pregnant or breastfeeding during the time when intensive screening is most important to manage their increased breast cancer risk. Despite this critical overlap, there is little evidence to guide clinicians on the appropriate screening for women with BRCA mutations during pregnancy or breastfeeding. Hormonal shifts that occur during pregnancy, the postpartum period, and breastfeeding result in changes to the breasts that may further complicate the sensitivity and specificity of screening modalities. We explore the safety and efficacy of available breast cancer screening modalities, including clinical breast exam, mammogram, breast MRI, and ultrasound among women with BRCA mutations who are pregnant or breastfeeding, providing recommendations from the most current published literature and expert opinion.
Keywords: BRCA; Breast MRI; Breast cancer screening; Breastfeeding; Clinical breast exam; Mammogram; PABC; Pregnant; Ultrasound.
Similar articles
-
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.JAMA. 2004 Sep 15;292(11):1317-25. doi: 10.1001/jama.292.11.1317. JAMA. 2004. PMID: 15367553
-
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.JAMA. 2006 May 24;295(20):2374-84. doi: 10.1001/jama.295.20.2374. JAMA. 2006. PMID: 16720823
-
Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.Cancer. 2011 Sep 1;117(17):3900-7. doi: 10.1002/cncr.25971. Epub 2011 Mar 1. Cancer. 2011. PMID: 21365619
-
Screening for hereditary breast cancer.Semin Oncol. 2007 Oct;34(5):392-400. doi: 10.1053/j.seminoncol.2007.07.002. Semin Oncol. 2007. PMID: 17920893 Review.
-
Reproductive issues for women with BRCA mutations.J Natl Cancer Inst Monogr. 2005;(34):83-6. doi: 10.1093/jncimonographs/lgi012. J Natl Cancer Inst Monogr. 2005. PMID: 15784831 Review.
Cited by
-
Breastfeeding and the patient's perspective.Abdom Radiol (NY). 2023 May;48(5):1629-1636. doi: 10.1007/s00261-022-03791-z. Epub 2023 Jan 10. Abdom Radiol (NY). 2023. PMID: 36625897 Review.
-
miR‑589‑3p sponged by the lncRNA TINCR inhibits the proliferation, migration and invasion and promotes the apoptosis of breast cancer cells by suppressing the Akt pathway via IGF1R.Int J Mol Med. 2020 Sep;46(3):989-1002. doi: 10.3892/ijmm.2020.4666. Epub 2020 Jul 2. Int J Mol Med. 2020. PMID: 32705168 Free PMC article.
-
Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.Cancers (Basel). 2022 Sep 22;14(19):4592. doi: 10.3390/cancers14194592. Cancers (Basel). 2022. PMID: 36230512 Free PMC article. Review.
-
Breast MRI during lactation: effects on tumor conspicuity using dynamic contrast-enhanced (DCE) in comparison with diffusion tensor imaging (DTI) parametric maps.Eur Radiol. 2020 Feb;30(2):767-777. doi: 10.1007/s00330-019-06435-x. Epub 2019 Sep 16. Eur Radiol. 2020. PMID: 31529255
-
Intravoxel incoherent motion (IVIM) and non-Gaussian diffusion MRI of the lactating breast.Eur J Radiol Open. 2018 Feb 2;5:24-30. doi: 10.1016/j.ejro.2018.01.003. eCollection 2018. Eur J Radiol Open. 2018. PMID: 29719854 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical